Iovance Biotherapeutics Inc (NASDAQ:IOVA)

34.18
Delayed Data
As of Mar 03
 -3.16 / -8.46%
Today’s Change
18.70
Today|||52-Week Range
54.21
-26.34%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$5.5B

Company Description

Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Contact Information

Iovance Biotherapeutics, Inc.
999 Skyway Road
San Carlos California 94070
P:(650) 260-7120
Investor Relations:

Employees

Shareholders

Mutual fund holders58.46%
Other institutional43.41%
Individual stakeholders0.64%

Top Executives

Maria FardisPresident, Chief Executive Officer & Director
Jean-Marc BelleminChief Financial Officer & Treasurer
Friedrich Graf FinckensteinChief Medical Officer
Michael C. SwartzburgChief Accounting Officer
Sara PellegrinoVP-Investor Relations & Public Relations